Full Breakdown
White House Denies President Donald Trump's Alleged Access to Experimental Obesity Drug Retatrutide
6/24/2026, 2:16:36 AM
Alleged Access to an Experimental Obesity Treatment
In April 2026 the U.S. Food and Drug Administration approved a compassionate-use request that allowed a 79-year-old male patient to receive retatrutide, an investigational weight-loss medication from Eli Lilly. The request, filed by National Institutes of Health senior clinician Ranganath Muniyappa, listed “refractory obesity with obstructive sleep apnea and pulmonary hypertension” as the patient’s conditions. Because the patient’s age matched President Donald Trump’s (who turned 80 in June 2026), STAT News asked whether the president was the recipient.
Regulatory and Clinical Background of Retatrutide
Eli Lilly describes retatrutide as a once-weekly triple-hormone receptor agonist currently in Phase 3 trials for obesity, type 2 diabetes, moderate-to-severe obstructive sleep apnea, and several cardiovascular and musculoskeletal outcomes. Trial data cited by Reuters showed an average 28 percent body-weight loss among participants. The FDA’s compassionate-use program is intended for patients with serious or immediately life-threatening conditions who lack comparable approved therapies.
Key Actors
- President Donald Trump – 79-year-old U.S. president; latest publicly released medical memo listed a weight of 238 lb and no diagnosis of sleep apnea or pulmonary hypertension.
- Kush Desai – White House spokesperson who responded to STAT’s inquiry on X.
- Steven Cheung – White House communications director who also addressed the report on X.
- Ranganath Muniyappa – NIH clinician who submitted the compassionate-use application.
- Eli Lilly – Manufacturer of retatrutide.
- U.S. Department of Health and Human Services (HHS) – Redirected STAT’s questions after the White House’s initial non-answer.
Data on the Compassionate-Use Request
- Patient age: 79 years.
- Conditions cited: refractory obesity, obstructive sleep apnea, pulmonary hypertension.
- Prior therapy: one year of tirzepatide with modest weight loss.
- Number of experts consulted by STAT: 18 bioethics scholars, obesity clinicians, and former health officials, all noting the request’s unusual nature.
Official Statements & Responses
The White House, via Kush Desai, categorically denied that the compassionate-use application was for President Trump, labeling the speculation “baseless.” Desai referenced a recent White House medical memo that omitted any mention of sleep apnea or pulmonary hypertension. HHS issued a standard comment affirming the FDA’s expanded-access policies without confirming the patient’s identity. The FDA confirmed the approval of the request. Eli Lilly declined to comment on the specific case while reiterating that compassionate-use is reserved for patients who cannot enroll in clinical trials.
Criticism & Opposition
Eighteen bioethics and clinical experts interviewed by STAT described the request as “unusual,” noting that obesity alone does not typically meet the life-threatening threshold required for compassionate use. Critics also highlighted the lack of public disclosure from Eli Lilly and the FDA, raising concerns about potential preferential treatment for well-connected individuals.
Conflicting Reports & Gaps
- No agency directly confirmed the patient’s identity.
- The White House memo listed Trump’s health as “excellent” but did not address the conditions cited in the compassionate-use request.
- Eli Lilly provided no specifics about the individual case.
- Media outlets reported varying tones in White House communications, from denial to personal attacks on the reporter.
Verbatim Quotes
- “Because this has to be spelled out for @LizzyLaw_, who has proven herself to be an unserious gossip columnist, this application was not for the President.” — Kush Desai, White House spokesperson
- “You certainly made a name for yourself by completely embarrassing yourself at the expense of being thirsty for clicks and peddling falsehoods.” — Steven Cheung, White House communications director
- “I probably should.” — Donald Trump, interview with The New York Times
- “excellent health, demonstrating strong cardiac, pulmonary, neurological, and overall physical function.” — White House medical memo (as reported by Newsweek)
What’s Next
Retatrutide remains in Phase 3 trials, with FDA approval expected later in 2026. President Trump’s next scheduled medical evaluation at Walter Reed National Military Medical Center may renew public scrutiny of his health disclosures. Ongoing media inquiries are likely to focus on the transparency of compassionate-use decisions for high-profile individuals.
